Gildeuretinol acetate is under clinical development by Alkeus Pharmaceuticals and currently in Phase III for Geographic Atrophy. According to GlobalData, Phase III drugs for Geographic Atrophy have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Gildeuretinol acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gildeuretinol acetate overview

Gildeuretinol acetate (ALK-001) is under development for the treatment of Stargardt's disease and geographic atrophy (GA). It is administered orally which is formulated as capsule. The drug candidate is a vitamin A enriched with deuterium (D3-vitamin A). It was under development for the treatment of intermediate atrophic macular degeneration.

Alkeus Pharmaceuticals overview

Alkeus Pharmaceuticals (Alkeus Pharma) is a clinical stage biopharmaceutical company. The company involves on discovery and development of treatments for eye disease. Its lead drug candidate ALK-001, an orally delivered compound used for the treatment of Stargardt disease. Alkeus Pharma is conducting its clinical trials on diseases such as Intermediate dry-AMD, Autosomal Recessive Retinitis Pigmentosa and Autosomal Recessive Cone-Rod Dystrophy among others. The company also develops novel therapeutic drugs for patients suffering from Leber’s hereditary optic neuropathy. Alkeus Pharma is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Gildeuretinol acetate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.